COMPOSIÇÕES CONTENDO ÁCIDO HIALURÔNICO, AMINOÁCIDOS E INTERMEDIÁRIOS DO CICLO DE KREBS ÚTEIS PARA AUMENTAR A EXPRESSÃO GÊNICA DA MATRIZ EXTRACELULAR
A combination of hyaluronic acid and specific amino acids and Krebs cycle intermediates effectively stimulates ECM gene expression and counters oxidative stress, addressing skin aging challenges.
Patent Information
- Application Number
- BR112025024192
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-05-07
- Publication Date
- 2026-11-10
AI Technical Summary
Current methods to counteract skin aging, such as avoiding sun exposure and using anti-UV sunscreens or natural compounds, are inadequate in promoting extracellular matrix (ECM) deposition and addressing oxidative stress-induced aging.
A composition combining hyaluronic acid with specific amino acids and Krebs cycle intermediates, specifically glycine, L-proline, L-leucine, L-lysine, L-valine, L-alanine, malic acid, and succinic acid, stimulates ECM gene expression and protects against oxidative stress.
The composition significantly enhances ECM gene expression and protects against oxidative stress-induced downregulation, promoting skin health and reducing aging effects.
Abstract
Description
1 / 11 Compositions containing hyaluronic acid, amino acids, and Krebs cycle intermediates useful for increasing gene expression in the extracellular matrix. TECHNICAL FIELD OF THE PRESENT INVENTION
[001] .The present invention relates to compositions for use in dermatology and cosmetics, comprising a mixture of hyaluronic acid, amino acids or salts thereof, and acids of the Krebs cycle, in particular malic and succinic acid or their salts. The compositions according to the present invention are useful for counteracting skin aging caused by decreased deposition of the extracellular matrix. BACKGROUND OF THE PRESENT INVENTION
[002] .In the human body, the skin is one of the organs most affected by the aging process. Nutritional approaches developed to counteract the age-related decline in extracellular matrix (ECM) deposition may represent a useful tool for reducing the degenerative processes underlying skin aging.
[003] .Skin aging is characterized by sequential and cumulative changes in skin structure and function, primarily attributable to a reduction in the production of its extracellular matrix (ECM) component (Shin et al., 2019; Sparavigna, 2020). The decline in ECM function causes loss of skin elasticity and resilience and the appearance of wrinkles, which is a typical characteristic of skin aging (Black et al., 2008; Sparaviga, 2020, Birch, 2018).Fibroblasts produce extracellular matrix (ECM) consisting mainly of proteins and glycosaminoglycans, whose main constituent is hyaluronic acid (HA), the key molecule involved in skin hydration due to its ability to bind and retain water molecules; a reduction in the content and activity of dermal HA during aging, resulting from both reduced synthesis and increased degradation by tissue hyaluronidase (HAse), therefore leads to dryness and loss of skin hydration (Papakonstantinou et al., 2012; Scarano et al., 2021). Petition 870250101588, dated 06 / 11 / 2025, page 9 / 72 2 / 11
[004] .The protein component of the ECM comprises fibrous proteins such as collagen, elastin, fibronectin, and laminin, characterized by a well-defined amino acid (AA) composition. Elastin (ELN) is the main protein responsible for skin elasticity, constituting approximately 2% of the total dermal proteins (Theocharis et al., 2016). ELN is synthesized through its soluble isoform tropoelastin, formed by alternating hydrophobic and hydrophilic domains. The hydrophobic domains are enriched with non-polar AAs, such as glycine, valine, proline, and alanine, arranged in repeating sequences of three to nine AAs, while the hydrophilic domains are enriched with alanine and lysine.Fibronectin (Fbn) plays a crucial role in cell binding, movement, and adhesion; Fbn, therefore, exhibits several binding patterns in its protein structure, characterized by defined AA sequences such as Arg-Gly-Asp, Arg-Gly-Asp-Ser, Leu-Asp-Val, and Arg-Glu-Asp-Val, which mediate the adhesion function of Fbn cells (Rosso et al., 2004). Collagen (Col) is the most abundant protein in mammals and represents the main component of the extracellular matrix (ECM), up to 75% in the dermis. Col has a triple helix structure derived from the molecular bond conferred by a rigid AA sequence, with repeated glycine-XY patterns, where glycine stabilizes the triple helix, and X and Y are frequently proline or hydroxyproline; Therefore, similarly to ELN and Fbn, Col exhibits a precise AA composition with a high percentage of glycine, hydroxyproline, proline, and alanine.The collagen family comprises 28 members, numbered from I to XXVIII; however, there are different isoforms within the same type of collagen, and the use of alternative promoters and other proteolytic cleavages gives rise to additional levels of diversity in the Col protein family (Vuorio and De Crombrugghe, 1990; Langton et al., 2010; Chu, 2011; Dalton and Lemmon, 2021).
[005] . In addition to the decline in the structural components of the ECM, the excessive production of reactive oxygen species (ROS) is another critical factor in skin aging. According to Harman's theory of aging, this process is mainly attributed to the decline in mitochondrial function, the Petition 870250101588, dated 06 / 11 / 2025, page 10 / 72 3 / 11 which leads to increased generation of ROS as byproducts of aerobic respiration; oxidative stress is therefore the main factor responsible for premature skin aging due to UV radiation, which damages mitochondrial DNA (mtDNA), causes oxidative phosphorylation dysfunction (OXPHOS) and increases ROS production (Ziada et al., 2020).
[006] . Currently, methods designed to slow down skin aging are based on preventive approaches, such as avoiding excessive sun exposure and / or the use of anti-UV sunscreens (Mohiuddin, 2019). At the same time, other treatment strategies involve supplementation with natural compounds, such as polyphenols, plant extracts, or HA, to mitigate age-related skin dryness. However, it has been shown that supplementing fibroblasts with a mixture of six amino acids (glycine, L-proline, L-leucine, L-lysine, L-valine, and L-alanine) increases the expression of ECM components. Furthermore, these six amino acids induce the expression of antioxidant genes (Tedesco et al., 2022). Both de novo protein synthesis and the remodeling and renewal of ECM components, which underlie its ability to sustain mechanotransductive and tensile properties, have a high energy cost, requiring increased mitochondrial ATP production (Roman et al., 2021). Stimulating mitochondrial activity can therefore help promote ECM deposition in fibroblasts and, by improving aerobic skin respiration, counteract skin aging induced by oxidative stress. DESCRIPTION OF THE PRESENT INVENTION
[007] It has now been discovered that a mixture of six amino acids, consisting of glycine, L-proline, L-leucine, L-lysine, L-valine and L-alanine, combined with hyaluronic acid, malic acid, succinic acid or pharmaceutically acceptable salts thereof, exerts synergistic effects in stimulating ECM gene expression. The objective of the present invention is therefore related to compositions comprising said amino acids combined with hyaluronic acid, malic acid and succinic acid, which are useful Petition 870250101588, dated 06 / 11 / 2025, p. 11 / 72 4 / 11 to combat skin aging. For this purpose, the compositions can be conveniently administered by injection, in the form of ready-to-use sterile solutions, or as lyophilized powders to be reconstituted with sterile water for injection. The compositions can also be in gel form for use as intradermal fillers. Alternatively, the formulations according to the present invention can also be used by topical or transdermal administration, for example, in the form of ointments, gels, creams and the like.
[008] .The weight proportions of the amino acids correspond substantially to the proportions present in collagen and elastin. The reciprocal proportions, using glycine as a reference, are preferably as follows: - Glycine 1; - L-proline: 0.7-0.8%, preferably 0.75. - L-alanine: 0.47-0.76, preferably 0.48-0.51, more preferably 0.75-0.76; - L-valine: 0.35-0.56; preferably 0.35-0.37 or 0.54-0.56; - L-leucine: 0.13-0.27; preferably 0.13-0.15. - L-lysine hydrochloride: 0.10-0.12; preferably 0.10-0.11.
[009] .The amino acid mixture in the proportions specified above is present in the compositions according to the present invention in concentrations ranging from 5 to 30%, preferably from 5 to 15%, by weight.
[0010] . The weight ratios of malic acid and succinic acid are preferably about 1:1. Malic and succinic acids or their salts are preferably present in concentrations of 1 to 5% by weight.
[0011] . Hyaluronic acid or its salts, in particular sodium hyaluronate, preferably have an average molecular weight of Mn ranging between 50,000 and 2,500,000 Da. The percentages of hyaluronic acid or sodium hyaluronate vary between 1 and 5% by weight of the total composition.
[0012] . For dermatological, cosmetic or therapeutic uses Petition 870250101588, dated 06 / 11 / 2025, p. 12 / 72 5 / 11 intended, the compositions according to the present invention will be administered subcutaneously or intradermally in amounts ranging from 0.1 to 10 ml, depending on the application site and the condition to be treated or prevented. In the case of topical administration, the formulations can be applied in amounts ranging from 0.1 to 10 g.
[0013] . The present invention is illustrated in detail in the following examples. EXAMPLE 1 INGREDIENTS Vial B - sterile solution WATER FOR INJECTION qs 1.5 ml GLYCINE 30.2 mg L-PROLINE 22.7 mg L-LEUCINE 4.2 mg L-LYSINE HCL 3.3 mg L-VALINE 16.8 mg L-ALANINE 22.8 mg SODIUM SUCCINATE 18 mg SODIUM MALATE 20.4 mg Ampoule (A) sterile solution WATER FOR INJECTION qs 1.5 ml SODIUM HYALURONATE 24 mg EXAMPLE 2 INGREDIENTS Bottle B - freeze-dried powder GLYCINE 30.2 mg L-PROLINE 22.7 mg L-LEUCINE 4.2 mg L-LYSINE HCL 3.3 mg L-VALINE 16.8 mg L-ALANINE 22.8 mg Petition 870250101588, dated 06 / 11 / 2025, page 13 / 72 6 / 11 INGREDIENTS Bottle B - lyophilized powder SODIUM SUCCINATE 18 mg SODIUM MALATE 20.4 mg Ampoule (A) sterile solution WATER FOR INJECTION qs 3 ml SODIUM HYALURONATE 30 MG EXAMPLE 3 INGREDIENTS Ampoule - Sterile solution WATER FOR INJECTION qs 3.5 ml SODIUM HYALURONATE 35 mg GLYCINE 38.6 mg L-PROLINE 29.1 mg L-LEUCINE 5.4 mg L-LYSINE HCL 4.2 mg L-VALINE 21.5 mg L-ALANINE 29.2 mg SODIUM SUCCINATE 18 mg SODIUM MALATE 20.4 mg EXAMPLE 4 PHARMACOLOGICAL EXPERIMENTS
[0014] . The most significant experiments conducted are described by way of example. In particular, the effects of a mixture of 6 amino acids enriched with HA (6AAH), supplemented with succinate (6AAHS), malate (6AAHM) or succinate / malate (6AAHSM), on ECM gene expression in human fibroblasts were studied both under basal conditions and in response to oxidative stress (hydrogen peroxide).
[0015] . Human BJ fibroblasts were supplemented with 6AAH, 6AAHS, 6AAHM, and 6AAHSM, and the mRNA levels of several ECM markers were evaluated. 6AAHSM increased the expression of all ECM markers significantly more than 6AAH, alone or in combination. Petition 870250101588, dated 06 / 11 / 2025, page 14 / 72 7 / 11 with succinate or malate. Furthermore, in an in vitro model of oxidative stress, 6AAHSM attenuated the decline in ECM gene expression induced by hydrogen peroxide. The data suggest that dietary supplementation with 6AAH enriched with malic and succinic acids is useful as a non-pharmacological approach to combat skin aging. MATERIALS AND METHODS Cell cultures and treatment
[0016] . Human skin fibroblasts (BJ) (ATCC® CRL-2522™) were cultured under standard conditions in EMEM medium (Sigma-Aldrich), supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cell cultures were incubated at 37°C, with 95% humidity and 5% CO2. Cells were treated with 0.1% (W / V) of the mixtures (composition shown in Table 1), + / - malic and succinic acid (5 mM each), for 3 days. Untreated cells were plated as a control. Every 24 hours, the media were replaced with fresh media or amino acid mixtures in both control and treatment flasks. Oxidative stress with hydrogen peroxide was conducted on cells pre-treated with culture medium alone or with the selected mixtures (Figure 3) for 24 hours; H2O2 (500 pM) was then added for 2 hours and, at the end of the experimental treatments, the cells were harvested for mRNA extraction. TABLE 1. COMPOSITION OF THE 6AAH MIXTURE Ingredient % of total Hyaluronic acid 30 Glycine 30 L-proline 22.7 L-leucine 4.2 L-lysine 3.3 L-valine 16.8 L-alanine 22.8 RNA extraction and quantitative RT-PCR
[0017] . For mRNA level analysis, 1 pg of total RNA, isolated Petition 870250101588, dated 06 / 11 / 2025, page 15 / 72 The 8 / 11 sample, obtained with the RNeasy kit (Qiagen), was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Italy). Triplicate PCR reactions were conducted on an iCycleriQ real-time PCR detection system (Bio-Rad Laboratories). The corresponding gene expression was calculated using a comparative method (2-ΔΔCt) using GAPDH as the maintenance gene. Primer sequences were designed using Beacon Designer 2.6 software (Premier Biosoft International, Palo Alto, CA, USA). Protein extraction and western blotting:
[0018] . Total proteins were extracted with the Reagent of Extraction of Mammalian Proteins M-PER (Pierce; ThermoScientific). Protein content was determined using the bicinchoninic acid (BCA) protein assay (Pierce); 30-40 pg of protein were analyzed on sodium dodecyl sulfate-polyacrylamide TGX gel with a 4-20% gradient (SDS-PAGE) (BioRad). The gels were transferred to PVDF, blocked with 5% skimmed milk powder, and incubated with anti-Fbnl antibodies (1:1000, GeneTex, Cat# GTX112794) or anti-vinculin antibodies (1:1000 Cat# V9131, Sigma-Aldrich). DESCRIPTION OF THE FIGURES
[0019] . Figure 1: Supplementation with malic / succinic acid increases mRNA expression of ECM markers. Quantitative RT-PCR analysis of ECM gene expression in BJ fibroblasts. Data are mean ± SEM of triplicate samples. NT: untreated controls, *P < 0.05 and **P < 0.01, vs. NT, $P < 0.05 and $P < 0.01 vs. 6AAH, #P < 0.05 and ##P < 0.01 vs. 6AAHS, §P < 0.05 and §§P < 0.01 vs. 6AAHM. One-way ANOVA followed by Tukey's post-hoc test.
[0020] . Figure 2: Supplementation with 6AAHSM induces Fbn expression. Western blot analysis (top panel) of Fbn protein in triplicate BJ samples. Vinculin was used as a loading control. Bottom panel: quantification of immunoblot data. CTRL: untreated controls, **P < 0.01 vs. NT and $P < 0.05 vs. 6AAH. One-way ANOVA followed by Tukey's post-hoc test. Petition 870250101588, dated 06 / 11 / 2025, p. 16 / 72 9 / 11
[0021] . Figure 3: Supplementation with 6AAHSM protects the ECM against oxidative stress. RT-PCR analysis of ECM markers in BJ fibroblasts treated with hydrogen peroxide. NT: untreated controls, hydrogen peroxide. Data are mean ± SEM of triplicate samples. *P < 0.05 and **P < 0.01, vs. NT, ^ P < 0.05 vs. H2O2, + P < 0.05 vs. 6AAH + H2O2. One-way ANOVA followed by Tukey's post-hoc test. RESULTS
[0022] The addition of malic and succinic acids to the 6-amino acid mixture increases the expression of the ECM gene to a significantly greater extent than the amino acids alone.
[0023] . The addition of succinic acid (6AAHS), malic acid (6AAHM), or succinic acid + malic acid (6AAHSM) to the 6AAH mixture increases the expression of the ECM markers Fbn, Elnl, and the two collagen isoforms collal and col4a1 compared to 6AAH, 6AAHM, or 6AAHS alone. On the other hand, although supplementation with 6AAH alone (at a final concentration of 0.1% w / v) did not modify Fbn expression compared to control cells (NT) (Fig. 1), the addition of succinate to the 6AAH mixture significantly increased the expression of Fbn mRNA levels for NTs and 6AAHs (+93% and +124%, respectively). Supplementation of 6AAH with malate also increased Fbn expression in 6AAHs (+152%) and controls (+116%).Similarly, supplementation with 6AAH malate and succinate (6AAHSM) significantly increased Fbn expression compared to controls (+167%) and 6AAH alone (+211%); however, 6AAHSM also induced Fbn expression to a greater extent (+38%) than 6AAHS alone. Analyzing Eln1 expression, only 6AAHSM significantly increased its expression compared to controls (+101%), while the other mixtures were almost ineffective. Likewise, Col1A1 and Col4A1 expression was significantly increased by 6AAHSM; in particular, Col1A1 was significantly increased by 6AAHSM supplementation alone (+85% vs. NT), while both 6AAHS and 6AAHSM induced significant expression of... Petition 870250101588, dated 06 / 11 / 2025, page 17 / 72 10 / 11 Col1A4 (+106% and +136% vs. NT, respectively); however, supplementation with 6AAHSM increased Col1A4 vs. NT to a greater extent than 6AAHS and 6AAHM (+255%, +72%, and +50% vs. NT, 6AAHS, and 6AAHM, respectively).
[0024] . Fbn has also been shown to play a crucial role in regulating and promoting the deposition of several other ECM components, including collagens (Sottile et al., 2007; Dalton and Lemmon, 2021). Fbn protein expression was therefore evaluated in BJ fibroblasts supplemented with culture media, 6AAH or 6AAHSM, which increased Fbn mRNA to a much greater extent than the other mixtures (Fig. 1). As shown in Fig. 2, 6AAHSM significantly increased Fbn protein expression compared to untreated or 6AAH-treated BJ fibroblasts, further validating the mRNA expression data and confirming that 6AAHSM regulates the deposition of ECM components; Furthermore, supplementation with a mixture of 6AAHs containing succinate and malate has a greater capacity to induce ECM gene expression than supplementation with 6AAHs containing succinate or malate alone.
[0025] . Having established that 6AAHSM was the most effective combination in inducing ECM gene expression, it was assessed whether this capacity also involves a greater ability to protect human fibroblasts against oxidative stress than the 6AAH mixture alone. For this purpose, BJ cells were pretreated with H2O2 or H2O2 plus 6AAH, or H2O2 plus 6AAHSM, and ECM gene expression was evaluated. As expected, while treatment with H2O2 reduced the expression of all ECM genes, supplementation with 6AAH was ineffective in restoring their expression, with the exception of Col1A4, which was significantly increased in 6AAH compared to H2O2 alone (Fig. 3). However, supplementation with 6AAHSM in H2O2 fibroblasts significantly reversed the oxidative stress-induced reduction of all ECM genes, with FBN and Col1A4 expression fully restored to control levels.
[0026] . These data suggest that the addition of malic and Petition 870250101588, dated 06 / 11 / 2025, p. 18 / 72 11 / 11 succinic acid, "as is" or in the form of pharmaceutically acceptable salts, increases the antioxidant capacity of the 6AAH mixture.
[0027] . The results demonstrate that the composition according to the present invention significantly stimulates the expression of the ECM gene in human fibroblasts, even at concentrations below 0.1%.
[0028] . Furthermore, the composition according to the present invention can reverse the downregulation of ECM gene expression induced by oxidative stress. BIBLIOGRAPHY Birch, HL (2018). in Subcellular Biochemistry, 169-190. Black, L.D., et al., Biophys. J. 94, 1916-1929. Chu, M. (2011). eLS. Dalton, C.J. and Lemmon, C.A. (2021).Cells 10. Langton, A. K. et al., (2010). Int. J. Cosmet. Sci. 32, 330-339. Mohiuddin, AK (2019). Globe. J. Med. Res., 15-60. Papakonstantinou, E. et al., (2012). Dermatoendocrinol. 4. doi: 10.4161 / derm.21923. Romani, et al., (2021). Nat. Freeze. Mol. Cell Biol. 22 , 22 – 38 . Rosso, F., (2004). J. Cell. Physiol. 199 , 174 – 180 . Scarano, A. et al. (2021). J. Cosmet. Dermatol. 20, 2296-2304. doi: 10.1111 / jocd.13811. Shin, JW, et al. (2019). They. J. Mol. Sci. 20. Sottile, J. et al., (2007) Am. J. Physiol. Cell Physiol. 293. doi: 10.1152 / ajpcell.00130.2007. Sparavigna, A. (2020). Plastic. Aesthetic Res. 2020. doi: 10.20517 / 2347-9264.2019.73. Tedesco, L., et al. (2022). Biosci. Biotechnol. Biochem. 86 , 1255 – 1261 . Theocharis, AD, (2016). Adv. Drug Deliv. Freeze. 97 , 4 – 27 . Vuorio, E., and De Crombrugghe, B. (1990). Year. Freeze. Biochem. 59 , 837 – 872 . Ziada, AS, Smith, MSR, and Côté, HCF (2020). Front. Cell Dev. Biol. 8. Petition 870250101588, dated 06 / 11 / 2025, p. 19 / 72
Claims
1 / 2 CLAIMS 1. COMPOSITION characterized in that it comprises: a. a mixture of amino acids consisting of glycine, L-proline, L-leucine, L-lysine, L-valine and L-alanine; b. hyaluronic acid or salts thereof; c. malic acid, succinic acid or pharmaceutically acceptable salts thereof.
2. COMPOSITION according to claim 1, characterized in that the weight proportions of the amino acids are: - Glycine 1; - L-Proline: 0.7-0.8; - L-Alanine: 0.47-0.76; - L-Valine: 0.35-0.56; - L-Leucine: 0.13-0.27; - L-Lysine hydrochloride: 0.10-0.
12.
3. COMPOSITION according to claim 1 or 2, characterized in that the weight ratio of malic acid to succinic acid is 1:
1.
4. COMPOSITION according to any one of claims 1 to 3, characterized in that the percentage by weight of the amino acid mixture is between 5 and 30%.
5. COMPOSITION according to any one of claims 1 to 4, characterized in that the percentage by weight of malic acid or a pharmaceutically acceptable salt thereof is between 1 and 5%.
6. COMPOSITION according to any one of claims 1 to 5, characterized in that the percentage by weight of succinic acid or a pharmaceutically acceptable salt thereof is between 1 and 5%.
7. COMPOSITION according to any one of claims 1 to 6, characterized in that the hyaluronic acid or its salts, in particular sodium hyaluronate, has an average molecular weight ranging between Petition 870250101588, dated 06 / 11 / 2025, page 20 / 72 2 / 2 50,000 and 2,500,000 Da, in percentages ranging from 1 to 5% by weight of the total composition.
8. COMPOSITION according to any one of claims 1 to 7, characterized in that it is in the form of sterile solutions for injection or in a form suitable for topical administration.
9. USE OF A COMPOSITION, as defined by one of claims 1 to 8, characterized in that it is for the manufacture of a medicament to combat and prevent skin aging. Petition 870250101588, dated 06 / 11 / 2025, p. 21 / 72
